In: Annals of Oncology, 2005, vol. 16, no. 7, p. 1061-1068
|
In: Annals of Oncology, 2007, vol. 19, no. 4, p. 793-800
|
In: International Journal of Cancer, 2012, p. -
Isolated limb perfusion (ILP) with melphalan and tumor necrosis factor (TNF)-α is used to treat bulky, locally advanced melanoma and sarcoma. However, TNF toxicity suggests a need for better-tolerated drugs. Cilengitide (EMD 121974), a novel cyclic inhibitor of alpha-V integrins, has both anti-angiogenic and direct anti-tumor effects and is a possible alternative to TNF in ILP. In this study,...
|